Some receptor tyrosine kinase inhibitors may exert negative effects on tumor-related lymphangiogenesis (and LN and distant organ metastases) by targeting the VEGF-C–VEGFR3 signaling pathway (105, 106). This evidence concerns the gene VEGFC and neoplasm.